{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:44:03Z","timestamp":1785365043897,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The production of advanced glycation end-products (AGEs) is a key pathomechanism related to the complications of diabetes mellitus. The measurement of HbA1c as one of the AGEs is widely used in the clinic, but also other proteins undergo glycation in the course of diabetes. Here, we measure skin AGEs (SAGEs) in patients with diabetes type 1 (DM1) and type 2 (DM2) and correlate them with metabolic markers as well as non-invasively measured liver fibrosis and steatosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>In this cross-sectional study, a total of 64 patients with either DM1 or DM2 and 28 healthy controls were recruited. SAGEs were measured using autofluorescence (AGE Reader). Liver fibrosis and steatosis were quantified using transient elastography, which determines liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). FGF19, FGF21 and GDF-15 were measured in blood samples using ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SAGEs were elevated in both groups of patients with diabetes as compared to healthy controls (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and were higher in patients with DM2 in comparison to DM1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006). SAGEs correlated positively with HbA1c (<jats:italic>r<\/jats:italic>\u2009=\u20090.404, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), CAP (<jats:italic>r<\/jats:italic>\u2009=\u20090.260, <jats:italic>p<\/jats:italic>\u2009=\u20090.016) and LSM (<jats:italic>r<\/jats:italic>\u2009=\u20090.356, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and negatively with insulin growth factor binding protein 3 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). We also detected a positive correlation between GDF15 and SAGEs (<jats:italic>r<\/jats:italic>\u2009=\u20090.469, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SAGEs are significantly elevated in patients with both DM types 1 and 2 and correlate with metabolic markers, including HbA1c and GDF15. They might also help to detect patients with advanced liver injury in the setting of diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-024-01558-9","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:02:39Z","timestamp":1709629359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Skin advanced glycation end-products as indicators of the metabolic profile in diabetes mellitus: correlations with glycemic control, liver phenotypes and metabolic biomarkers"],"prefix":"10.1186","volume":"24","author":[{"given":"Grigorios","family":"Christidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"K\u00fcppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senem Ceren","family":"Karatayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersin","family":"Karatayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne N.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"10","key":"1558_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrendo.2016.105","volume":"12","author":"P Zimmet","year":"2016","unstructured":"Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016;12(10):616\u201322.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1558_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/db16-0806","volume":"66","author":"JS Skyler","year":"2017","unstructured":"Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of diabetes by Pathophysiology, Natural History, and prognosis. Diabetes. 2017;66(2):241\u201355.","journal-title":"Diabetes"},{"issue":"1","key":"1558_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","volume":"17","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Horm (Athens). 2018;17(1):61\u20137.","journal-title":"Horm (Athens)"},{"issue":"10","key":"1558_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","volume":"19","author":"Q Yang","year":"2018","unstructured":"Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol. 2018;19(10):654\u201372.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 1","key":"1558_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice C","year":"2022","unstructured":"American Diabetes Association Professional Practice C. 2. Classification and diagnosis of diabetes: standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):17\u2013S38.","journal-title":"Diabetes Care"},{"key":"1558_CR6","doi-asserted-by":"crossref","unstructured":"Aragno M, Mastrocola R. Dietary sugars and endogenous formation of Advanced Glycation endproducts: emerging mechanisms of Disease. Nutrients. 2017;9(4).","DOI":"10.3390\/nu9040385"},{"issue":"2","key":"1558_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s001250051591","volume":"44","author":"R Singh","year":"2001","unstructured":"Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129\u201346.","journal-title":"Diabetologia"},{"issue":"1","key":"1558_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14756361003733621","volume":"26","author":"MI Choudhary","year":"2011","unstructured":"Choudhary MI, Abbas G, Ali S, Shuja S, Khalid N, Khan KM, et al. Substituted benzenediol Schiff bases as promising new anti-glycation agents. J Enzyme Inhib Med Chem. 2011;26(1):98\u2013103.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"1558_CR9","first-page":"50","volume":"4","author":"NA Ansari","year":"2013","unstructured":"Ansari NA, Dash D. Amadori glycated proteins: role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging Dis. 2013;4(1):50\u20136.","journal-title":"Aging Dis"},{"issue":"1099","key":"1558_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/postgradmedj-2016-134579","volume":"93","author":"C Da Moura Semedo","year":"2017","unstructured":"Da Moura Semedo C, Webb M, Waller H, Khunti K, Davies M. Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Postgrad Med J. 2017;93(1099):289\u201394.","journal-title":"Postgrad Med J"},{"issue":"2","key":"1558_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.numecd.2021.10.007","volume":"32","author":"Q Jin","year":"2022","unstructured":"Jin Q, Lau ES, Luk AO, Ozaki R, Chow EY, So T, et al. Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: a prospective cohort study from the Hong Kong diabetes biobank. Nutr Metab Cardiovasc Dis. 2022;32(2):436\u201346.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"1558_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00125-018-4769-x","volume":"62","author":"RP van Waateringe","year":"2019","unstructured":"van Waateringe RP, Fokkens BT, Slagter SN, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia. 2019;62(2):269\u201380.","journal-title":"Diabetologia"},{"issue":"9","key":"1558_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jdiacomp.2018.06.009","volume":"32","author":"S Osawa","year":"2018","unstructured":"Osawa S, Katakami N, Sato I, Ninomiya H, Omori K, Yamamoto Y, et al. Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes. J Diabetes Complications. 2018;32(9):839\u201344.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"1558_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3109\/02713683.2014.918152","volume":"40","author":"M Yasuda","year":"2015","unstructured":"Yasuda M, Shimura M, Kunikata H, Kanazawa H, Yasuda K, Tanaka Y, et al. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. Curr Eye Res. 2015;40(3):338\u201345.","journal-title":"Curr Eye Res"},{"issue":"2","key":"1558_CR15","doi-asserted-by":"publisher","first-page":"101273","DOI":"10.1016\/j.diabet.2021.101273","volume":"48","author":"A Larroumet","year":"2022","unstructured":"Larroumet A, Foussard N, Majchrzak C, Monlun M, Blanco L, Mohammedi K, et al. Skin autofluorescence predicts mortality in type 1 diabetes. Diabetes Metab. 2022;48(2):101273.","journal-title":"Diabetes Metab"},{"issue":"12","key":"1558_CR16","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1681\/ASN.2005020144","volume":"16","author":"R Meerwaldt","year":"2005","unstructured":"Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16(12):3687\u201393.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324\u201330.","journal-title":"Diabetologia"},{"issue":"5","key":"1558_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jhep.2010.10.012","volume":"54","author":"E Maury","year":"2011","unstructured":"Maury E, Vergniol J, Ledinghen V, Rigalleau V. Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation End products. J Hepatol. 2011;54(5):1079\u201380.","journal-title":"J Hepatol"},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.12659\/MSM.915806","volume":"25","author":"J Dai","year":"2019","unstructured":"Dai J, Chen H, Chai Y. Advanced Glycation End products (AGEs) induce apoptosis of fibroblasts by activation of NLRP3 inflammasome via reactive oxygen species (ROS) signaling pathway. Med Sci Monit. 2019;25:7499\u2013508.","journal-title":"Med Sci Monit"},{"issue":"1","key":"1558_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/hmbci-2020-0075","volume":"42","author":"H Razmi","year":"2021","unstructured":"Razmi H, Tarighat-Esfanjani A, Payahoo L, Mobasseri M, Amirpour M, Mirzaei E, et al. Relationship between the levels of serum fibroblast growth factor 19 and metabolic factors in obese and normal weight subjects with and without type 2 diabetes mellitus: a case-control study. Horm Mol Biol Clin Investig. 2021;42(1):11\u20137.","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"11","key":"1558_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654\u201367.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1558_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","volume":"33","author":"SA Kliewer","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15\/19 pathway. Dig Dis. 2015;33(3):327\u201331.","journal-title":"Dig Dis"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"FM Fisher","year":"2016","unstructured":"Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223\u201341.","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"1558_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.21037\/atm.2018.05.26","volume":"6","author":"Z Shan","year":"2018","unstructured":"Shan Z, Alvarez-Sola G, Uriarte I, Arechederra M, Fernandez-Barrena MG, Berasain C, et al. Fibroblast growth factors 19 and 21 in acute liver damage. Ann Transl Med. 2018;6(12):257.","journal-title":"Ann Transl Med"},{"issue":"6","key":"1558_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1381612825666190402101143","volume":"25","author":"L Fang","year":"2019","unstructured":"Fang L, Li F, Gu C. GDF-15: a multifunctional modulator and potential therapeutic target in Cancer. Curr Pharm Des. 2019;25(6):654\u201362.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"1558_CR26","first-page":"494","volume":"116","author":"BM May","year":"2021","unstructured":"May BM, Pimentel M, Zimerman LI, Rohde LE. GDF-15 as a Biomarker in Cardiovascular Disease. Arq Bras Cardiol. 2021;116(3):494\u2013500.","journal-title":"Arq Bras Cardiol"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"490842","DOI":"10.1155\/2015\/490842","volume":"2015","author":"R Adela","year":"2015","unstructured":"Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015:490842.","journal-title":"J Diabetes Res"},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ahj.2020.12.020","volume":"234","author":"X Bao","year":"2021","unstructured":"Bao X, Borne Y, Xu B, Orho-Melander M, Nilsson J, Melander O, et al. Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: a prospective study. Am Heart J. 2021;234:81\u20139.","journal-title":"Am Heart J"},{"issue":"10","key":"1558_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","volume":"17","author":"D Wang","year":"2021","unstructured":"Wang D, Day EA, Townsend LK, Djordjevic D, Jorgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592\u2013607.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1558_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1089\/dia.2011.0034","volume":"13","author":"DC Bos","year":"2011","unstructured":"Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol Ther. 2011;13(7):773\u20139.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"1558_CR31","doi-asserted-by":"publisher","first-page":"10895","DOI":"10.3390\/s140610895","volume":"14","author":"SF Khalil","year":"2014","unstructured":"Khalil SF, Mohktar MS, Ibrahim F. The theory and fundamentals of bioimpedance analysis in clinical status monitoring and diagnosis of diseases. Sens (Basel). 2014;14(6):10895\u2013928.","journal-title":"Sens (Basel)"},{"issue":"5","key":"1558_CR32","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"7","key":"1558_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/dia.2010.0014","volume":"12","author":"MJ Noordzij","year":"2010","unstructured":"Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Skin autofluorescence and glycemic variability. Diabetes Technol Ther. 2010;12(7):581\u20135.","journal-title":"Diabetes Technol Ther"},{"issue":"29","key":"1558_CR34","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.3748\/wjg.v27.i29.4913","volume":"27","author":"E Pereira","year":"2021","unstructured":"Pereira E, Paula DP, de Araujo BP, da Fonseca MJM, Diniz M, Daliry A, et al. Advanced glycation end product: a potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol. 2021;27(29):4913\u201328.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1558_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clinbiochem.2005.07.016","volume":"39","author":"E Yagmur","year":"2006","unstructured":"Yagmur E, Tacke F, Weiss C, Lahme B, Manns MP, Kiefer P, et al. Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem. 2006;39(1):39\u201345.","journal-title":"Clin Biochem"},{"issue":"1","key":"1558_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0168-8278(01)00232-X","volume":"36","author":"K Sebekova","year":"2002","unstructured":"Sebekova K, Kupcova V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol. 2002;36(1):66\u201371.","journal-title":"J Hepatol"},{"issue":"35","key":"1558_CR37","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","volume":"22","author":"C Leung","year":"2016","unstructured":"Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, et al. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(35):8026\u201340.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"1558_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.04943.x","volume":"22","author":"H Hyogo","year":"2007","unstructured":"Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22(7):1112\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pharmthera.2019.02.008","volume":"198","author":"SJ Baek","year":"2019","unstructured":"Baek SJ, Eling T. Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases. Pharmacol Ther. 2019;198:46\u201358.","journal-title":"Pharmacol Ther"},{"key":"1558_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2020.11.002","volume":"57","author":"AC Eddy","year":"2021","unstructured":"Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. Cytokine Growth Factor Rev. 2021;57:11\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7795","key":"1558_CR41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138.","journal-title":"Nature"},{"issue":"9","key":"1558_CR42","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.7150\/ijbs.25026","volume":"14","author":"J Zhang","year":"2018","unstructured":"Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci. 2018;14(9):1000\u201311.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"1558_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3346\/jkms.2016.31.9.1413","volume":"31","author":"MY Shin","year":"2016","unstructured":"Shin MY, Kim JM, Kang YE, Kim MK, Joung KH, Lee JH, et al. Association between growth differentiation factor 15 (GDF15) and Cardiovascular Risk in patients with newly diagnosed type 2 diabetes Mellitus. J Korean Med Sci. 2016;31(9):1413\u20138.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"1558_CR44","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/jcp.30158","volume":"236","author":"MX Wu","year":"2021","unstructured":"Wu MX, Wang SH, Xie Y, Chen ZT, Guo Q, Yuan WL, et al. Interleukin-33 alleviates diabetic cardiomyopathy through regulation of endoplasmic reticulum stress and autophagy via insulin-like growth factor-binding protein 3. J Cell Physiol. 2021;236(6):4403\u201319.","journal-title":"J Cell Physiol"},{"key":"1558_CR45","doi-asserted-by":"crossref","unstructured":"Cai Q, Dozmorov M, Oh Y. IGFBP-3\/IGFBP-3 receptor system as an Anti-tumor and Anti-metastatic Signaling in Cancer. Cells. 2020;9(5).","DOI":"10.3390\/cells9051261"},{"issue":"6","key":"1558_CR46","doi-asserted-by":"publisher","first-page":"e22912","DOI":"10.1002\/jcla.22912","volume":"33","author":"YL Hou","year":"2019","unstructured":"Hou YL, Luo P, Ji GY, Chen H. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;33(6):e22912.","journal-title":"J Clin Lab Anal"},{"issue":"11","key":"1558_CR47","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ejca.2005.04.023","volume":"41","author":"AM Burger","year":"2005","unstructured":"Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41(11):1515\u201327.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1558_CR48","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s13277-013-1405-8","volume":"35","author":"F Tas","year":"2014","unstructured":"Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol. 2014;35(4):3125\u201332.","journal-title":"Tumour Biol"},{"issue":"5","key":"1558_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/br.2016.629","volume":"4","author":"F Tas","year":"2016","unstructured":"Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep. 2016;4(5):609\u201314.","journal-title":"Biomed Rep"},{"issue":"10","key":"1558_CR50","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1158\/1055-9965.EPI-11-0179","volume":"20","author":"S Rohrmann","year":"2011","unstructured":"Rohrmann S, Linseisen J, Becker S, Allen N, Schlehofer B, Overvad K, et al. Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European prospective investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2174\u201382.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:08:35Z","timestamp":1709928515000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01558-9","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the ethical committee of \u00c4rztekammer Saarland (approval number 84\/19). The study was performed in accordance with the Declaration of Helsinki. All recruited subjects provided signed informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}